---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032465"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2026-10-13T10:01:58+00:00"
generated_at: "2026-10-13T10:05:35.529766+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell preliminary Q3 2026 sales $8.0M, up 46% YoY; nine-month sales $25.6M, up 27.8%

## Summary
- Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase over Q3 2025; domestic sales were $6.9 million, up 29.2%.
- Nine-month 2026 sales were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025.
- Growth was broad-based: Tri-Shield rose 51% over Q3 2025, Dual-Force 36%, and the recently launched functional feed line 37%.
- CFO Timothy Fiori said the comparison was aided by depressed Q3 2025 sales caused by high distributor purchases in Q2 2025.
- ImmuCell will discontinue early sales reporting; CEO Olivier te Boekhorst will discuss full Q3 results on a call November 13, 2026 at 9:00 AM ET.

## SEC filing metadata
- accession: 0001437749-26-032465
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2026-10-13T10:01:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/0001437749-26-032465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/iccc20261009_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032465
- JSON: https://secwatch.observer/filing/0001437749-26-032465.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.